Bayer AG: Positive Developments in Prescription Drugs

Bayer AG (i.) has started the 2025 fiscal year steadily and confirms its annual targets despite a still challenging market environment, particularly in the agricultural and consumer goods sectors. The company benefited from improved operating results, a significant increase in free cash flow, and clear progress in the implementation of strategic priorities. CEO Bill Anderson sees Bayer clearly on track to drive the transformation of the company consistently forward. In the Crop Science business, price pressure and a difficult North American market...